• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»artificial intelligence in healthcare

Why Tempus AI’s Lens upgrade matters for precision oncology drug development

By Pallavi Madhiraju on June 1, 2026   Medical Devices & Diagnostics  

Why Tempus AI’s Lens upgrade matters for precision oncology drug development

Tempus AI expands Lens with agentic AI for oncology drug development. Find out how it could reshape trials, evidence generation and biopharma R&D.

Is WHOOP quietly turning its fitness band into a front door for healthcare?

By Pallavi Madhiraju on May 11, 2026   Medical Devices & Diagnostics  

Is WHOOP quietly turning its fitness band into a front door for healthcare?

Wearables collect more health data than ever. WHOOP is betting clinicians and AI can turn that flood into real decisions.

Can ZEISS turn ophthalmology workflow software into the next battleground in cataract care?

By Pallavi Madhiraju on April 7, 2026   Medical Devices & Diagnostics  

Can ZEISS turn ophthalmology workflow software into the next battleground in cataract care?

ZEISS unveiled new AI, cataract planning, and cloud workflow tools at ASCRS 2026. Read what this means for ophthalmology practices.

From lung scans to heart risk signals: what McLaren Health Care’s AI rollout reveals about preventive care

By Pallavi Madhiraju on February 18, 2026   Medical Devices & Diagnostics  

From lung scans to heart risk signals: what McLaren Health Care’s AI rollout reveals about preventive care

Discover how McLaren Health Care is using AI on routine CT scans to detect heart disease earlier and what it means for preventive cardiology.

Recent Posts

  • Can Pfizer’s $10.5bn Innovent deal rebuild confidence in its oncology pipeline?
  • Nuvalent’s ALK inhibitor gets Priority Review as lung cancer treatment sequencing evolves
  • Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?
  • Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity
  • AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer
  • Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?
  • Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes